丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000513 丽珠集团

已收盘 05-28 15:00:00

{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":39.03,"timestamp":1716879783000,"preClose":39.38,"halted":0,"volume":4339312,"delay":0,"floatShares":598000000,"shares":927999999,"eps":2.134,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.35,"latestTime":"05-28 15:00:00","open":39.27,"high":39.59,"low":38.91,"amount":170000000,"amplitude":0.0173,"askPrice":39.04,"askSize":16,"bidPrice":39.03,"bidSize":320,"shortable":0,"etf":0,"ttmEps":2.134,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716946200000},"adr":0,"adjPreClose":39.38,"symbolType":"stock","openAndCloseTimeList":[[1716859800000,1716867000000],[1716872400000,1716879600000]],"highLimit":43.32,"lowLimit":35.44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":927651978,"pbRate":2.5,"roa":"--","roe":"4.25%","epsLYR":2.1,"committee":0.677524,"marketValue":36206000000,"floatMarketCap":23336000000,"peRate":18.289596,"changeRate":-0.0089,"turnoverRate":0.0073,"status":1},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2435312605","title":"华福证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2435312605","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435312605?lang=zh_cn&edition=full","pubTime":"2024-05-13 14:55","pubTimestamp":1715583317,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华近期对丽珠集团进行研究并发布了研究报告《创新+高壁垒制剂齐头并进，长期发展动力充沛》，本报告对丽珠集团给出买入评级，当前股价为40.89元。我们认为， 公司基本盘稳固， 创新管线丰富， 是国内仿转创的龙头企业， 首次覆盖给予“买入” 评级。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为45.17。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300007706.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432187597","title":"丽珠集团获得发明专利授权：“植入注射器”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432187597","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2432187597?lang=zh_cn&edition=full","pubTime":"2024-05-04 02:12","pubTimestamp":1714759922,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示丽珠集团新获得一项发明专利授权，专利名为“植入注射器”，专利申请号为CN202010211031.7，授权日为2024年5月3日。今年以来丽珠集团新获得专利授权3个，较去年同期增加了50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050400001738.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430083370","title":"健友股份与丽珠集团合作 注射用醋酸西曲瑞克首次出口美国","url":"https://stock-news.laohu8.com/highlight/detail?id=2430083370","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2430083370?lang=zh_cn&edition=full","pubTime":"2024-04-28 13:36","pubTimestamp":1714282560,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯 4月27日，健友股份与丽珠集团合作的注射用醋酸西曲瑞克首次出口美国。本次注射用醋酸西曲瑞克将于近期安排在美国上市销售，惠及更多患者。健友股份通过寻求与中国优质制药企业合作方式，充分发挥在美国市场多年的运营经验，深入挖掘国内优质产品管线，通过产品合作、技术合作等多种方式，携手中国优秀的制药企业，共同进入美国市场。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-28/doc-inatkkuz0764117.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-28/doc-inatkkuz0764117.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430273884","title":"东吴证券：给予丽珠集团买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430273884","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430273884?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:40","pubTimestamp":1714131652,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对丽珠集团进行研究并发布了研究报告《2024年一季报点评：促性领域及诊断试剂板块业绩亮眼，整体营利稳健》，本报告对丽珠集团给出买入评级，当前股价为38.98元。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为44.36。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600049178.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430849286","title":"丽珠集团（000513）2024年一季报简析：净利润增4.45%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430849286","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430849286?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:07","pubTimestamp":1713996459,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期丽珠集团发布2024年一季报。根据财报显示，本报告期中丽珠集团净利润增4.45%，盈利能力上升。截至本报告期末，公司营业总收入32.43亿元，同比下降4.99%，归母净利润6.08亿元，同比上升4.45%。重仓丽珠集团的前十大基金见下表：持有丽珠集团最多的基金为广发均衡增长混合A，目前规模为22.63亿元，最新净值1.011，较上一交易日上涨0.52%，近一年上涨3.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500011810.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429402163","title":"丽珠集团(000513.SZ)发布一季度业绩，净利润6.08亿元，增长4.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429402163","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429402163?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:00","pubTimestamp":1713862853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠集团(000513.SZ)发布2024年一季度报告，报告期内实现营业收入32.43亿元，同比下降4.99%。归属于上市公司股东的净利润6.08亿元，同比增长4.45%。归属于上市公司股东的扣除非经常性损益的净利润5.9亿元，同比增长3.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107532.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2416941721","title":"丽珠集团(000513.SZ)已耗资7343.65万元回购股份215.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2416941721","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2416941721?lang=zh_cn&edition=full","pubTime":"2024-03-04 17:29","pubTimestamp":1709544540,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)发布公告，截至2024年2月29日，公司通过集中竞价交易方式回购了公司A股股份共计215.26万股，占公司总股本的比例为0.23%，购买的最高价为人民币35.15元/股，最低价为人民币32.95元/股，已使用的资金总额为人民币7343.65万元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-04/doc-inamczvm0771405.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-04/doc-inamczvm0771405.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2409416518","title":"减肥药“跑赢”科技！巨头携手创新高，A股概念股也“嗨了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2409416518","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2409416518?lang=zh_cn&edition=full","pubTime":"2024-02-06 11:52","pubTimestamp":1707191576,"startTime":"0","endTime":"0","summary":"诺和诺德扩产大消息","market":"us","thumbnail":"https://img3.gelonghui.com/088cf-ab38441b-8fb9-49ba-b8bc-0bcdcd5c9933.jpg?guru_height=851&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/088cf-ab38441b-8fb9-49ba-b8bc-0bcdcd5c9933.jpg?guru_height=851&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/692268","is_publish_highlight":false,"gpt_icon":0},{"id":"2408509169","title":"丽珠集团(000513.SZ)已耗资5340万元回购155.35万股A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2408509169","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2408509169?lang=zh_cn&edition=full","pubTime":"2024-02-01 17:27","pubTimestamp":1706779620,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)发布公告，截至2024年1月31日，公司通过集中竞价交易方式回购了公司A股股份共计155.35万股，占公司总股本的比例为0.17%，购买的最高价为人民币35.15元/股，最低价为人民币33.73元/股，已使用的资金总额为人民币5340万元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-01/doc-inafpshw0434467.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-01/doc-inafpshw0434467.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2394767967","title":"丽珠集团袁蔼铃：顶层设计是ESG重中之重 2022年投入近1亿元保护环境","url":"https://stock-news.laohu8.com/highlight/detail?id=2394767967","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2394767967?lang=zh_cn&edition=full","pubTime":"2023-12-28 11:52","pubTimestamp":1703735520,"startTime":"0","endTime":"0","summary":"新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。　　在公司研讨会环节，丽珠集团ESG发展总监兼证券事务经理（H股）袁蔼铃女士向嘉宾们介绍了近年来丽珠集团ESG发展历程、ESG管治水平提升、以及2022年的ESG具体实践和经营成果。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpuna7412430.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpuna7412430.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2394266762","title":"丽珠集团杨亮：国际机构评级与国内国情有差异，将把更多中国特色元素加入ESG报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2394266762","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2394266762?lang=zh_cn&edition=full","pubTime":"2023-12-28 11:43","pubTimestamp":1703734980,"startTime":"0","endTime":"0","summary":"新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。　　作为中国及全球范围内多个细分领域领先的综合医药集团公司，丽珠集团深入落实ESG管理理念与公司发展战略的融合，是中国医药企业ESG实践的先行者。怀抱“做医药行业领先者”的企业愿景，丽珠集团持续关注全球制药研发领域新化学实体和前沿技术，切实提高药品可及性和可负担性，为守护公众健康砥砺前行。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpumx7717470.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpumx7717470.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2394622627","title":"东方证券ESG研究负责人薛俊：丽珠集团的ESG改善行动让人出乎意料","url":"https://stock-news.laohu8.com/highlight/detail?id=2394622627","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2394622627?lang=zh_cn&edition=full","pubTime":"2023-12-28 11:41","pubTimestamp":1703734860,"startTime":"0","endTime":"0","summary":"新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。在研讨会上，东方证券首席策略分析师、ESG负责人薛俊表示，丽珠集团在ESG改善行动上的举措让其出乎意料。　　据介绍，MSCI近期公布最新年度ESG评级结果，丽珠集团评级由AA级上调至全球最高等级AAA级，成为中国制药行业中首家获得MSCI ESG最高AAA评级的企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpunf7044734.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/esg/ep/2023-12-28/doc-imzzpunf7044734.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2394257952","title":"“顶流”密集出手三大赛道，“抄作业”的时候到了","url":"https://stock-news.laohu8.com/highlight/detail?id=2394257952","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2394257952?lang=zh_cn&edition=full","pubTime":"2023-12-25 18:22","pubTimestamp":1703499720,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　虽然未到业绩报告期，但12月以来多家上市公司因回购、定增等事项披露了前十大流通股东的变动情况。　　这就让一些知名基金经理的动作藏不住了，综合来看，人工智能、医药、新能源及大消费等赛道均有基金看好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2023-12-25/doc-imzzfpwv2986360.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2023-12-25/doc-imzzfpwv2986360.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2390230874","title":"健康元药业集团股份有限公司关于丽珠集团控股子公司丽珠试剂申请在新三板挂牌的进展公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2390230874","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2390230874?lang=zh_cn&edition=full","pubTime":"2023-12-11 01:41","pubTimestamp":1702230060,"startTime":"0","endTime":"0","summary":"有关本次挂牌的详情请见本公司发布的《健康元药业集团股份有限公司关于丽珠集团终止筹划其控股子公司分拆至创业板上市并申请在新三板挂牌的公告》。丽珠试剂本次挂牌不涉及发行股份。　　本次挂牌尚需提交丽珠集团股东大会、丽珠试剂董事会及股东大会审议通过，且需经全国中小企业股份转让系统有限责任公司核准，筹备和申请挂牌时间、申请结果亦存在不确定性。　　健康元药业集团股份有限公司　　二〇二三年十二月十一日","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2023-12-11/doc-imzxqhcp2607336.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2023-12-11/doc-imzxqhcp2607336.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2388240693","title":"丽珠集团(000513.SZ)：重组新冠融合蛋白二价疫苗(CHO细胞)纳入紧急使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2388240693","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2388240693?lang=zh_cn&edition=full","pubTime":"2023-12-03 16:28","pubTimestamp":1701592080,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)发布公告，2023年12月1日，公司控股附属公司珠海市丽珠单抗生物技术有限公司(以下简称“丽珠单抗”)收到国家相关部门的函件，丽珠单抗研发生产的重组新型冠状病毒融合蛋白二价(原型株/OmicronXBB变异株)疫苗(CHO细胞)经国家卫生健康委提出建议，国家药品监督管理局(以下简称“国家药监局”)组织论证同意纳入紧急使用。该品是继重组新型冠状病毒融合蛋白疫苗(丽康V-01)之后，公司第二款被国家纳入紧急使用的新冠疫苗产品。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-03/doc-imzwtpav5322008.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-03/doc-imzwtpav5322008.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","stockEarnings":[{"period":"1week","weight":-0.0008},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0504},{"period":"6month","weight":0.1319},{"period":"1year","weight":0.0426},{"period":"ytd","weight":0.1248}],"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","perCapita":"13733股","boardName":"医药制造业","registeredCapital":"92765万元","compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.036},{"period":"6month","weight":0.0339},{"period":"1year","weight":-0.0275},{"period":"ytd","weight":0.0501}],"survey":"　　丽珠医药集团股份有限公司以医药产品的研发、生产及销售为主业，主要产品涵盖制剂产品、原料药和中间体及诊断试剂及设备，主要产品包括壹丽安（艾普拉唑肠溶片及注射用艾普拉唑钠）、丽珠得乐（枸橼酸铋钾）系列产品、丽倍乐（雷贝拉唑钠肠溶胶囊）、维三联（枸橼酸铋钾片/替硝唑片/克拉霉素片）、贝依（注射用醋酸亮丙瑞林微球）、丽申宝（注射用尿促卵泡素）、乐宝得（注射用尿促性素）、丽福康（注射用伏立康唑）、瑞必乐（马来酸氟伏沙明片）、康尔汀（盐酸哌罗匹隆片）、参芪扶正注射液、抗病毒颗粒等制剂产品；美伐他汀、阿卡波糖、硫酸粘菌素、苯丙氨酸、盐酸万古霉素、达托霉素、米尔贝肟及头孢曲松钠等原料药和中间体；肺炎支原体IgM抗体检测试剂（胶体金法）、人类免疫缺陷病毒抗体诊断试剂盒（酶联免疫法）及抗核抗体检测试剂盒（磁条码免疫荧光发光法）等诊断试剂产品。","serverTime":1716884206829,"listedPrice":6.38,"stockholders":"43538人(较上一季度减少1.54%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}